Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENVISION phase 3 study of SRP-9001 in ambulatory and non-ambulatory Duchenne muscular dystrophy
jRCT2033230274Phase 3Not yet recruiting
- Sponsor
- Sarepta Therapeutics
- Start
- Sep 2023
- Modality
- Gene Therapies
01
Overview
Phase 3, randomised, double-blind trial of delandistrogene moxeparvovec in Duchenne muscular dystrophy (DMD) (2 arms), sponsored by Sarepta Therapeutics. Primary endpoint: Change from baseline in Performance of Upper Limb total score. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
delandistrogene moxeparvovec
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on jRCT2033230274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033230274.